Clinical spectrum and ascertainment pathways in pediatric female dystrophinopathy
- 1Department of Neurology, Capital Center for Children’s Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, 100020 China
- 2Department of Medical Genetics, Capital Center for Children’s Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, 100020 China
- 3Beijing Key Laboratory of Advanced Nucleic Acid Drug Delivery and Clinical Translation of Major Genetic Diseases, Beijing, 100020 China
Abstract
Background: Pediatric female dystrophinopathy may be asymptomatic at evaluation or may show skeletal muscle and cardiac manifestations, but childhood presentations are often subtle. We aimed to characterize the clinical spectrum, ascertainment pathways, subclinical muscle involvement, and inheritance patterns in this population.
Methods: This single-center retrospective case series was conducted between January 2024 and December 2025 and included 35 girls with genetically confirmed DMD gene variants identified from existing clinical records. Primary ascertainment route was recorded separately from cross-sectional clinical status at evaluation and classified as symptom-driven presentation, incidental or unexplained hyperCKemia, family-based cascade screening, or incidental genomic discovery. Clinical status at evaluation was assigned after systematic clinical review with reference to published female dystrophinopathy classifications. Statistical analyses were exploratory.
Results: The median age was 5 years (range, 1–10). Primary ascertainment routes were symptom-driven presentation in 8/35 (22.9%), incidental or unexplained hyperCKemia in 18/35 (51.4%), family-based cascade screening in 8/35 (22.9%), and incidental genomic discovery in 1/35 (2.9%). After systematic clinical review, clinical status at evaluation was classified as asymptomatic in 29 participants, BMD-like in 1, DMD-like in 3, and cardiac-symptom/CMR observations in 2. All 18 girls initially identified through incidental or unexplained hyperCKemia were classified as asymptomatic because no muscle weakness was documented on neurological examination, although some had exercise intolerance, easy fatigue, myalgia, or cramps. EMG abnormalities were identified in 14/34 participants, including definite myopathic findings in 5 and subtle short-duration motor-unit-potential changes in 9. Variants were apparently de novo in 15 cases, maternally inherited in 18, and paternally inherited in 2, including one case inherited from a father with low-level mosaicism in peripheral blood.
Conclusions: Pediatric female dystrophinopathy shows a broad childhood spectrum and may be recognized before objective muscle weakness is documented. Separating ascertainment route from clinical status highlights recurrent or persistent hyperCKemia and mild exercise-related complaints as practical entry points for targeted neuromuscular assessment and longitudinal follow-up. Earlier recognition in childhood may support timely neuromuscular and cardiac surveillance, parental evaluation when appropriate, family-based genetic counseling, and future reproductive planning.
Related
- Cord-Derived Stem Cells for Pediatric Autism Spectrum Disorder: Biological Rationale and Source-Specific Trial Design
- The mutational and clinical spectrum of EYS-associated retinitis pigmentosa in an Eastern European and Northern Asian cohort: two recurrent founder alleles
- Expanding the clinical and molecular spectrum of Schaaf-Yang syndrome in China: evidence for a severe phenotypic subgroup associated with MAGEL2 c.1996-Region variants
- Clinical and MEFV variant characteristics of pediatric patients with an FMF-compatible phenotype and PFAPA-compatible features in a Palestinian referral cohort: a retrospective study
- Gut microbiota dysbiosis in pediatric acute lymphoblastic leukemia: clinical consequences, mechanistic insights, and microbiota-targeted interventions.
BibTeX
@article{jiao2026clinical,
title = {{Clinical spectrum and ascertainment pathways in pediatric female dystrophinopathy}},
author = {Hui Jiao and Jinli Bai and Ping Li and Jing Sun and Dongqing Li and Jianzhao Zhang and Yujin Qu and Xiaoyin Peng},
journal = {Italian Journal of Pediatrics},
year = {2026},
month = jul,
doi = {10.1186/s13052-026-02312-8},
url = {https://doi.org/10.1186/s13052-026-02312-8},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Clinical spectrum and ascertainment pathways in pediatric female dystrophinopathy
AU - Hui Jiao
AU - Jinli Bai
AU - Ping Li
AU - Jing Sun
AU - Dongqing Li
AU - Jianzhao Zhang
AU - Yujin Qu
AU - Xiaoyin Peng
PY - 2026
DA - 2026/07/01
JO - Italian Journal of Pediatrics
DO - 10.1186/s13052-026-02312-8
UR - https://doi.org/10.1186/s13052-026-02312-8
AB - Background: Pediatric female dystrophinopathy may be asymptomatic at evaluation or may show skeletal muscle and cardiac manifestations, but childhood presentations are often subtle. We aimed to characterize the clinical spectrum, ascertainment pathways, subclinical muscle involvement, and inheritance patterns in this population. Methods: This single-center retrospective case series was conducted between January 2024 and December 2025 and included 35 girls with genetically confirmed DMD gene variants identified from existing clinical records. Primary ascertainment route was recorded separately from cross-sectional clinical status at evaluation and classified as symptom-driven presentation, incidental or unexplained hyperCKemia, family-based cascade screening, or incidental genomic discovery. Clinical status at evaluation was assigned after systematic clinical review with reference to published female dystrophinopathy classifications. Statistical analyses were exploratory. Results: The median age was 5 years (range, 1–10). Primary ascertainment routes were symptom-driven presentation in 8/35 (22.9%), incidental or unexplained hyperCKemia in 18/35 (51.4%), family-based cascade screening in 8/35 (22.9%), and incidental genomic discovery in 1/35 (2.9%). After systematic clinical review, clinical status at evaluation was classified as asymptomatic in 29 participants, BMD-like in 1, DMD-like in 3, and cardiac-symptom/CMR observations in 2. All 18 girls initially identified through incidental or unexplained hyperCKemia were classified as asymptomatic because no muscle weakness was documented on neurological examination, although some had exercise intolerance, easy fatigue, myalgia, or cramps. EMG abnormalities were identified in 14/34 participants, including definite myopathic findings in 5 and subtle short-duration motor-unit-potential changes in 9. Variants were apparently de novo in 15 cases, maternally inherited in 18, and paternally inherited in 2, including one case inherited from a father with low-level mosaicism in peripheral blood. Conclusions: Pediatric female dystrophinopathy shows a broad childhood spectrum and may be recognized before objective muscle weakness is documented. Separating ascertainment route from clinical status highlights recurrent or persistent hyperCKemia and mild exercise-related complaints as practical entry points for targeted neuromuscular assessment and longitudinal follow-up. Earlier recognition in childhood may support timely neuromuscular and cardiac surveillance, parental evaluation when appropriate, family-based genetic counseling, and future reproductive planning.
SN - 1824-7288
SN - 1720-8424
ER -